fbpx Skip to main content

Minnesota Yaz Lawsuit Filed over Deep Vein Thrombosis

By February 27, 2012July 15th, 2019Uncategorized

Blood clots and deep vein thrombosis were the subject of a recent Yaz lawsuit that was filed on February 7 in the Minnesota District Court by plaintiff Jamee Schaefer-Oney.

Schaefer-Oney’s complaint states that Bayer, the makers of Yaz, didn’t properly warn her of Yaz’s dangers before she started taking the pill. After taking Yaz, Schaefer-Oney developed a pulmonary embolism, which is a commonly known side effect of the drug. Her condition occurred within months of her taking Yaz.

Her complaint specifically says that Bayer Healthcare Pharmaceuticals, “did not provide adequate warnings to doctors, the healthcare community and the general public about the increased risk of serious adverse events.” Bayer has continued to maintain that Yaz, Yasmin and other drospirenone-based pills are no more dangerous to take than older pills that don’t contain drospirenone. This stubbornness by Bayer has caused the FDA to force the company to issue stronger warnings against Yaz and Yasmin, but to the patients that have already suffered from the debilitating conditions caused by the pills, those warnings came too late.

Some of the side effects that have been linked to Yaz include: heart attacks, strokes, gallbladder disease and blood clots that can lead to pulmonary embolisms and deep vein thrombosis. Early in February, two other women filed Yaz lawsuits after they claim that the pills caused them to suffer from gallbladder disease that required surgery to have their gallbladder’s removed. February has been a big month for Yaz lawsuits to be filed and it doesn’t appear to be slowing down anytime soon. If you have suffered from any of the side effects linked to Yaz, you may want to contact an attorney to see what your options are.

While lawsuits can’t correct the damage that these dangerous drugs cause, the can help to hold big name drug companies like Bayer accountable for their irresponsible actions in trying to promote their drug’s off label uses while hiding the dangers from consumers and healthcare professionals.